Quarterly report · Q3
2342.TEDINET S100STDC
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.7bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥11.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥52m | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥153m | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥51m | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥199m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥385m | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥7m | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥344m | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥38m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥410m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥182m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥43m | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥171m | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥10.4bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥10.9bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.4bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥4.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.0bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥6.1bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.8bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥-2.27 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.15 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.32 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.81 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.54 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 56.7% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.4% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 32
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥5m |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-12-31 | ¥450,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥5m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥152m |
| jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥5m |
| jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥109m |
| jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥8.1bn |
| jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥8.1bn |
| jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥760,000 |
| jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥313m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥9.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥9.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥204m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥4m |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-12-31 | ¥2m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥157m |
| jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.8bn |
| jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.8bn |
| jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5m |
| jpcrp040300-q3r_E05317-000Drug Discovery Support Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥132m |
| jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥6.7bn |
| jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥6.7bn |
| jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1m |
| jpcrp040300-q3r_E05317-000Investments And Consulting Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥179m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥8.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥8.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥310m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 361
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |